Researchers have uncovered a crucial mechanism through which a toxin produced by a common intestinal bacterium can damage the colon and contribute to conditions associated with colorectal cancer. The discovery could open new possibilities for developing treatments that stop the harmful process before it causes further damage.

The research, led by scientists at Johns Hopkins University, focuses on Bacteroides fragilis, a bacterium that can live in the digestive systems of healthy people. While many strains are harmless, certain varieties produce a toxin known as BFT, which can disrupt the protective lining of the intestine and encourage chronic inflammation.

The team has now identified the previously unknown protein that the toxin uses to gain access to colon cells. Even more importantly, researchers developed a specially designed molecular decoy that intercepted the toxin and protected mice from its damaging effects.

A Hidden Weakness in the Colon’s Protective Barrier

The human colon is lined with closely connected cells that form a protective barrier. This layer helps prevent harmful substances from entering deeper tissues while allowing nutrients and other necessary materials to pass through.

Earlier investigations showed that the BFT toxin attacks a protein called E-cadherin. This protein helps neighbouring intestinal cells remain connected. When the toxin damages E-cadherin, the protective structure becomes weaker, potentially triggering inflammation and other harmful changes.

However, scientists had struggled to explain how the toxin reached E-cadherin in the first place. It did not appear to attach directly to its target, suggesting that another protein was acting as an entry point.

The new study has helped solve this long-standing mystery.

Claudin-4 Identified as the Toxin’s Entry Point

To find the missing connection, researchers used CRISPR-based gene screening, a technology that allows scientists to switch off individual genes and observe how cells respond.

By examining colon-lining cells with different genes disabled, the team identified claudin-4 as the key protein required for BFT to attach to the cells.

Claudin-4 normally contributes to the tight junctions that hold neighbouring cells together and help regulate the movement of substances across the intestinal lining.

When researchers removed the gene responsible for producing claudin-4, the bacterial toxin could no longer attach effectively. As a result, it also lost access to E-cadherin, the protein it normally damages.

Additional laboratory experiments confirmed that BFT and claudin-4 can bind directly to one another, providing strong evidence for the newly identified interaction.

Researchers Create a Molecular Decoy

Identifying the toxin’s attachment point gave scientists an opportunity to explore a possible method of preventing the damage.

The research team designed a soluble protein containing selected portions of claudin-4. Instead of allowing the toxin to connect with claudin-4 on the surface of intestinal cells, this specially developed molecule was intended to attract and capture BFT first.

The approach worked in experimental testing.

When the decoy was introduced, the toxin attached to the substitute protein rather than targeting the colon cells. Experiments in mice showed that this strategy protected intestinal tissue against damage caused by BFT.

The result offers an encouraging starting point for future treatment research. Instead of trying to repair the intestinal barrier after it has been injured, scientists may eventually be able to stop the toxin at the earliest stage of its attack.

Does This Mean a Cure for Colon Cancer Is Near?

The findings are promising, but researchers caution against interpreting the results as a new cancer cure.

The protective effect was demonstrated in laboratory and animal experiments. Scientists have not yet established whether the molecular decoy can safely prevent toxin-related disease or colorectal cancer in humans.

Further research will be needed to improve the molecule, understand how it behaves inside the human body and determine whether it can be developed into a practical treatment.

The presence of Bacteroides fragilis in the digestive system also does not automatically indicate a cancer risk. The bacterium can occur in healthy individuals, and the harmful effects discussed in the study are associated with toxin-producing strains.

A Promising Direction for Future Medical Research

The discovery provides a clearer explanation of how a bacterial toxin interacts with the human intestine. It also identifies a potential target for therapies aimed at preventing toxin-related damage.

Published in the journal Nature in April 2026, the research builds on years of investigations into the relationship between gut bacteria, chronic inflammation and colorectal cancer.

If future studies confirm that the decoy strategy is safe and effective in humans, it could contribute to new approaches for managing diseases associated with bacterial toxins.

For now, the achievement represents an important advance in understanding how certain microorganisms can influence intestinal health and how scientists might interrupt their harmful activity.